Anaroxyl5 mg/ml

Anaroxyl is a hemostatic (antihemorrhagic) and capillary-protective agent used to help reduce oozing-type bleeding related to increased capillary fragility and permeability. Its use can be classified by strength of supporting evidence as follows:

Established/commonly used indications

• Reduction of capillary bleeding (oozing) during and after minor surgical, dental, ENT (e.g., tonsillectomy), and gynecological procedures, used as an adjunct alongside standard surgical hemostatic technique.
• Management of bleeding associated with increased capillary fragility, such as purpura and easy bruising of capillary origin.
• Symptomatic control of epistaxis (nosebleeds) of capillary origin, as an adjunct to standard first-aid measures.

Adjunct / combination-therapy uses

• As an adjunct to other hemostatic measures (e.g., local pressure, packing, or definitive surgical hemostasis) rather than as a stand-alone treatment for significant or ongoing hemorrhage.
• Adjunctive use in menorrhagia (heavy menstrual bleeding) believed to be related to capillary fragility, typically alongside other gynecologic management.

Uses with limited/evolving evidence

• Use in hemorrhoidal bleeding and some ophthalmic (retinal/vitreous) capillary hemorrhage settings has been explored, but supporting evidence is less robust and use is considered adjunctive/off-label in these settings.

Anaroxyl is not a substitute for identifying and treating the underlying cause of significant bleeding, nor for definitive surgical or coagulation-based hemostatic intervention when these are required.

Monosemicarbazone Adrenochrome is available as the sole active pharmaceutical ingredient in oral tablet form and, in some markets, as an injectable solution for intramuscular or intravenous use. Strength and excipients vary by manufacturer and formulation; check the product label for the exact composition of the specific brand dispensed.

Anaroxyl (also known as carbazochrome) is a synthetic semicarbazone derivative of adrenochrome, the oxidation product of epinephrine (adrenaline). Unlike epinephrine, it does not act as a vasoconstrictor, a pressor agent, or a systemic anticoagulant/procoagulant. Instead, it acts locally to reduce capillary permeability and fragility, helping to limit oozing-type capillary bleeding. It is used as a hemostatic and vascular-protective agent in selected surgical, dental, and minor bleeding contexts.

Hemostatic agent; capillary-protective (vascular-stabilizing) agent.

Mechanism of Action

Monosemicarbazone Adrenochrome reduces the permeability and fragility of capillary walls, helping to limit abnormal oozing from small vessels. It is thought to interact with vascular endothelium and platelet alpha-adrenoreceptors, promoting normal platelet adhesiveness and aggregation at the site of capillary injury without producing a generalized procoagulant or vasoconstrictive effect. Importantly, Monosemicarbazone Adrenochrome does not significantly affect systemic blood pressure, heart rate, or the coagulation cascade (clotting factors), which distinguishes it from vasopressor agents and systemic anticoagulant-reversal drugs.

Pharmacokinetics

Detailed human pharmacokinetic data (absorption, distribution, metabolism, elimination) for Monosemicarbazone Adrenochrome are limited in the published literature; clinical dosing is based on established empirical regimens rather than extensive pharmacokinetic modeling.

Oral tablets of Anaroxyl may be taken with or without food and swallowed whole with a glass of water. The injectable form of Anaroxyl must only be administered by a qualified healthcare professional via intramuscular or slow intravenous injection; it should never be self-injected at home.

No well-established, clinically significant drug-drug interactions have been documented for Anaroxyl in the available literature. As a general precaution, tell your physician about all other medicines, supplements, and herbal products you are taking, particularly other hemostatic, antifibrinolytic, or anticoagulant agents, since concurrent use with Anaroxyl has not been systematically studied and a theoretical additive or antagonistic effect on bleeding/clotting cannot be entirely excluded.

Anaroxyl is generally well tolerated. Reported adverse effects are usually mild and infrequent, and may include:

• Nausea or mild gastrointestinal discomfort (with oral use)
• Skin rash or hypersensitivity reactions
• Injection-site pain, redness, or irritation (with injectable use)
• Headache or dizziness (uncommon)

Seek medical attention if signs of a serious allergic reaction (e.g., swelling of the face/throat, difficulty breathing, widespread rash) occur while taking Anaroxyl.

Data on the use of Anaroxyl in human pregnancy and lactation are limited. As with any medicine lacking well-established safety data in pregnancy, Anaroxyl should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. It is not known whether Anaroxyl passes into breast milk; caution is advised, and a physician should be consulted before use during breastfeeding.

Anaroxyl is intended as an adjunctive measure to help reduce capillary-type bleeding and is not a substitute for identifying and treating the underlying cause of significant or persistent bleeding, or for definitive surgical, endoscopic, or coagulation-based hemostatic intervention when these are indicated. Some regulatory and clinical reviews have noted that evidence for the efficacy of Anaroxyl is considered modest or limited when assessed against modern rigorous clinical-trial standards, compared with more extensively validated hemostatic agents; it should be used with this evidence context in mind and not relied upon alone for serious hemorrhage. Anaroxyl has a favorable overall safety profile, and precautions mainly relate to hypersensitivity (see Contraindications) and the need for prompt medical evaluation of any significant, worsening, or unexplained bleeding rather than self-treatment with Anaroxyl alone.

There is limited published data on human overdose with Anaroxyl, and no specific antidote is known. If an overdose of Anaroxyl is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, and must be provided by qualified medical personnel. Do not attempt to manage a suspected overdose of Anaroxyl at home.

Store Anaroxyl at room temperature (below 30°C), away from light and moisture. Keep the injectable form of Anaroxyl protected from direct light. Keep out of reach of children.

Elderly

No specific dose adjustment is generally required for Anaroxyl in elderly patients, but the lowest effective dose should be used with routine clinical monitoring.

Renal/Hepatic Impairment

Well-established dosing guidance for renal or hepatic impairment is not available; use Anaroxyl with caution and physician oversight in these patients.

Pediatric Patients

Safety and efficacy of Anaroxyl have not been well established in children (see Pediatric Uses).

Anaroxyl is typically used short-term, for the duration of an acute bleeding episode or as short-term perioperative prophylaxis (often just a few days), unless a physician advises longer-term use for a chronic capillary-fragility condition. Treatment duration with Anaroxyl should be determined by the prescribing physician based on clinical response.

Hemostatics; capillary-protective (vascular-stabilizing) agents; semicarbazone derivatives of adrenochrome.

Monosemicarbazone Adrenochrome reduces capillary wall permeability and fragility and promotes normal platelet adhesiveness at the site of capillary injury, without significant systemic vasoconstrictor, pressor, or anticoagulant/procoagulant activity.

The safety and efficacy of Anaroxyl in pediatric patients have not been well established. Use of Anaroxyl in children should occur only when a physician determines it is clearly necessary, with close monitoring and an appropriately reduced dose if prescribed.